The Efficacy and Safety of Azithromycin for Patients with Cystic Fibrosis: A Systematic Review

Suardiani, Luh Adi Kusuma and Suastini, Ni Made and Herawati, Fauna (2022) The Efficacy and Safety of Azithromycin for Patients with Cystic Fibrosis: A Systematic Review. Jurnal Ilmiah Kesehatan (Journal of Health Science), 15 (2). pp. 98-106. ISSN 1978-6743; e-ISSN 2477-3948

PDF Fauna Herawati_The Efficacy and Safety of Azithromycin.pdf Download (662kB)

Abstract

Azithromycin has antimicrobial, immunomodulatory, and anti-inflammatory effects for chronic inflammatory processes in cystic fibrosis (CF). This systematic review evaluates the effectiveness and safety of azithromycin as a potential therapy for CF patients. The authors assessed the efficacy of azithromycin using the FEV1 and the drug's safety by comparing adverse effects. Furthermore, we also reviewed secondary outcomes, consisting of Forced vital capacity (FVC) values and pro-inflammatory indicators. In addition, they consist of exacerbations, bodyweight gain, and quality of life. The authors searched the published literature using online databases PUBMED and Cochrane Library published until March 9, 2021. The keywords were "Azithromycin" and "Cystic fibrosis" with the Boolean operator "AND" with no restrictions in publication year and research design. We conducted a critical study using the Critical Appraisal Skills Program (CASP) and Jadad score to minimize bias. Findings from eight journals showed that five studies reported increased mean FEV1 after giving azithromycin in patients with CF. Three studies notified increased FVC, and four research reported decreased pro-inflammatory indicators, namely CRP, IL-8, and neutrophils. Two papers reported a significant weight gain. Two studies informed improved the patients' quality of life. In addition, three publications did not report any significant or severe side effects. The most common adverse effect informed by the other four studies were rash in two studies, diarrhea in two studies, nausea, and fever in two studies. In conclusion, we consider azithromycin administration for CF patients is relatively safe and welltolerated.

Item Type:	Article
Uncontrolled Keywords:	Cystic Fibrosis, Azithromycin, Efficacy, Safety
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Faculty of Pharmacy > Department of Pharmacy
Depositing User:	Ester Sri W. 196039
Date Deposited:	04 Aug 2022 02:19
Last Modified:	04 Aug 2022 02:21
URI:	http://repository.ubaya.ac.id/id/eprint/42262

Actions (login required)

View Item